- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02290561
SmartTarget THERAPY
SmartTarget - A Magnetic Resonance Image to Ultrasound Fusion System for Targeted Prostate Intervention: Therapy
The purpose of this study is to assess how accurately SmartTarget can direct high intensity focused ultrasound (HIFU) to a pre-defined area (cancer) in the prostate.
The current standard methods for treating prostate cancer are directed to the whole gland - either surgery to remove it or radiotherapy. An alternative method is focal therapy. This is surgery that uses an energy source to ablate the cancer whilst preserving the normal healthy tissue.
Prior to surgery prostate cancer can often be localised using MRI imaging and detailed prostate biopsy techniques. The difficulty is that during surgery it is very difficult to accurately locate the cancer on the live ultrasound images - to compensate surgeons will treat half or a quarter of the prostate to ensure that the cancer is treated. This may cause higher rates of side-effects.
SmartTarget is an MRI to ultrasound fusion device that maps the pre-treatment MRI onto the live ultrasound during surgery. It then provides a target for the surgeons to treat during the operation.
The results will measure if the area intended to treat was covered and if how accurate the treatment was by comparing the pre-treatment MRI with a 1 week post treatment scan
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Não aplicável
Contactos e Locais
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Histological diagnosis of prostate cancer (PSA </=15ng/ml, Gleason score </=4+3, and radiological stage </=T3aNoMo)
- Prostate biopsy concordant with mpMRI lesion (template transperineal or MRI-targeted biopsy only)
- Discrete lesion on mpMRI scoring 3, 4 or 5 on radiological scale of suspicion
- mpMRI carried out according to European Society of Uro-Radiology guidelines at 1.5T or 3T
- An understanding of the English language sufficient to understand written and verbal information about the trial and consent process
- Signed informed consent
Exclusion Criteria:
- No lesion on mpMRI
- Bilateral lesions on mpMRI
- mpMRI undertaken over 6 months prior to visit 1
- Contralateral Gleason >/=3+4 and/or Maximum Cancer Core Length Involvement >/=6mm
- Men who have taken any form of hormones (except 5-alpha reductase inhibitors) within the last 6 months
- Prior immunosuppression or predefined immunosuppressed state
- An irreversible coagulopathy predisposing to bleeding
- Unable to undergo transrectal ultrasonography
- Previous radiation therapy to the pelvis
- Previous HIFU, cryosurgery, thermal, irreversible electroporation, radiofrequency or microwave therapy to the prostate.
- Men with evidence of metastatic disease or nodal disease outside the prostate on bone scan or cross-sectional imaging
- Men not fit for major surgery as assessed by a consultant anaesthetist
- Men who are unable to give informed consent
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Target Ablation
Prazo: 1 week post treatment
|
The ability of SmartTarget-directed focal HIFU therapy to ablate an intended target within the prostate, as measured by the proportion of men in whom complete ablation of the target region is achieved.
Complete or incomplete ablation is determined by a comparative assessment of the pre-therapy and one week post-therapy contrast-enhanced MRIs by an expert radiologist.
|
1 week post treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Accuracy
Prazo: 1 week post treatment
|
The accuracy of SmartTarget guided focal HIFU measured by the relative treatment volume and relative ablation volume on the one week post treatment.
|
1 week post treatment
|
Length of the procedure
Prazo: intraoperative
|
The efficiency and clinical usability of the SmartTarget device as measured by the: Length of the procedure The time taken during the procedure using SmartTarget, including: The total prostate computer model generation time The total time taken to register (fuse) MRI and ultrasound image data and the number of times an image registration is performed using SmartTarget (the re-registration rate) SmartTarget failure rate |
intraoperative
|
Quality of Life
Prazo: 6 weeks and 3 months
|
To assess how this treqatment strategy impacts on quality of life as measured using validated questionnaires at 6 weeks and 3 months post treatment. IPSS IIEF EQ5D - 5L |
6 weeks and 3 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Hashim U Ahmed, FRCS PhD, University College, London
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 14/0389
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Ressonância magnética
-
Rennes University HospitalBayerRescindidoEsclerose Múltipla (EM) | Doença InflamatóriaFrança
-
Memorial Sloan Kettering Cancer CenterRecrutamento
-
Memorial Sloan Kettering Cancer CenterNational Institutes of Health (NIH)Ativo, não recrutandoCâncer de Cabeça e PescoçoEstados Unidos
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)RescindidoOsteossarcoma | Sarcoma de Ewing | Doença de PagetEstados Unidos
-
Seoul National University Bundang HospitalBayerConcluídoTraumaRepublica da Coréia
-
American College of Radiology Imaging NetworkNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupDesconhecidoCâncer de mama | BIRADS 3 | BIRADS 4 | BIRADS 5Estados Unidos
-
Chang Gung Memorial HospitalRecrutamentoCâncer de próstata | Imagem de ressonância magnética | Teste controlado e aleatórioTaiwan
-
Reto Sutter, MDRecrutamentoImagem de ressonância magnéticaSuíça
-
Five Eleven Pharma, Inc.Indiana UniversityRecrutamento
-
Radboud University Medical CenterDesconhecidoNeoplasias da Mama | Neoplasias retaisHolanda